Chimeric Antigen Receptor T-Cell Therapy.

Abstract

Patients with relapsed or refractory (R/R) cancers have a poor prognosis and limited treatment options. The recent approval of 2 chimeric antigen receptor (CAR) autologous T-cell products for R/R B-cell acute lymphoblastic leukemia and non-Hodgkin's lymphoma treatment is setting the stage for what is possible in other diseases. However, there are important factors that must be considered, including patient selection, toxicity management, and costs associated with CAR T-cell therapy. To begin to address these issues, NCCN organized a task force consisting of a multidisciplinary panel of experts in oncology, cancer center administration, and health policy, which met for the first time in March 2018. This report describes the current state of CAR T-cell therapy and future strategies that should be considered as the application of this novel immunotherapy expands and evolves.

• Authors: Ndiya Ogba, Nicole M Arwood, Nancy L Bartlett, Mara Bloom, Patrick Brown, Christine Brown, Elizabeth Lihua Budde, Robert Carlson, Stephanie Farnia, Terry J Fry, Morgan Garber, Rebecca A Gardner, Lauren Gurschick, Patricia Kropf, Jeff J Reitan, Craig Sauter, Bijal Shah, Elizabeth J Shpall, Steven T Rosen
• Journal: Journal of the National Comprehensive Cancer Network : JNCCN (J Natl Compr Canc Netw) Vol. 16 Issue 9 Pg. 1092-1106 (09 2018) ISSN: 1540-1413 [Electronic] United States
• PMID: 30181421 (Publication Type: Journal Article)
• Copyright: Copyright © 2018 by the National Comprehensive Cancer Network.

Chemical References

• Receptors, Chimeric Antigen

Topics

• Advisory Committees
• Cancer Care Facilities (organization & administration)
• Drug Resistance, Neoplasm (immunology)
• Health Policy
• Humans
• Immunotherapy, Adoptive (adverse effects, methods, trends)
• Interdisciplinary Communication
• Medical Oncology (organization & administration)
• Neoplasm Recurrence, Local (immunology, therapy)
• Neoplasms (immunology, therapy)
• Receptors, Chimeric Antigen (immunology)
• Societies, Medical (organization & administration)
• T-Lymphocytes (immunology, transplantation)
• Transplantation, Autologous (adverse effects, methods, trends)
• United States